ClinicaliQ Trial Snapshot
- A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) — Recruiting • Phase I • Oncology • NCT05562830.
- Treatment being tested: Investigational agents administered alone or in combination with pembrolizumab (a PD-1 inhibitor) in patients with PD-1/L1-refractory urothelial carcinoma, addressing an unmet clinical need in treatment-resistant disease.
- Patient eligibility overview: The substudy enrolls patients with locally advanced or metastatic urothelial carcinoma who have demonstrated progression or inadequate response to prior PD-1/L1 checkpoint inhibitor therapy, representing a challenging patient population with limited options.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This substudy is part of an umbrella platform study which is designed to evaluate investigational agents with or without pembrolizumab in participants with urothelial carcinoma who are in need of new treatment options. Substudy 04A will enroll participants with locally advanced or mUC whose disease is resistant to treatment with programmed cell death-1/ligand 1 (PD-1/L1) inhibitors. The protocol infrastructure will enable the rolling assignment of investigational treatments.
Eligibility Snapshot
- : The main inclusion and
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.